Invention Grant
- Patent Title: Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells
-
Application No.: US15400096Application Date: 2017-01-06
-
Publication No.: US11028177B2Publication Date: 2021-06-08
- Inventor: Jennifer Brogdon , Saar Gill , Carl H. June , Michael D. Kalos , Andreas Loew , John Scholler
- Applicant: Novartis AG , The Trustees of the University of Pennsylvania
- Applicant Address: CH Basel; US PA Philadelphia
- Assignee: Novartis AG,The Trustees of the University of Pennsylvania
- Current Assignee: Novartis AG,The Trustees of the University of Pennsylvania
- Current Assignee Address: CH Basel; US PA Philadelphia
- Agency: Lando & Anastasi, LLP
- Main IPC: C07K16/22
- IPC: C07K16/22 ; C07K16/28 ; C07K14/725 ; C07K14/705 ; A61K35/17 ; A61K35/28 ; A61K38/17 ; A61K39/395 ; A61K39/00
Abstract:
The invention provides compositions and methods for treating leukemia, for example, acute myeloid leukemia (AML) and B-cell acute lymphoid leukemia (B-ALL). The invention also relates to at least one chimeric antigen receptor (CAR) specific to CD123, vectors comprising the same, and recombinant T cells comprising the CD123 CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a CD123 binding domain. The invention also includes methods of bone marrow ablation for use in treatments necessitating bone marrow reconditioning or transplant.
Public/Granted literature
Information query
